IN2014MN02437A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN02437A IN2014MN02437A IN2437MUN2014A IN2014MN02437A IN 2014MN02437 A IN2014MN02437 A IN 2014MN02437A IN 2437MUN2014 A IN2437MUN2014 A IN 2437MUN2014A IN 2014MN02437 A IN2014MN02437 A IN 2014MN02437A
- Authority
- IN
- India
- Prior art keywords
- lysin
- antibiotic
- bacteria
- linezolid
- oxacillin
- Prior art date
Links
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 3
- 230000003115 biocidal effect Effects 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 108010013198 Daptomycin Proteins 0.000 abstract 1
- 241000192125 Firmicutes Species 0.000 abstract 1
- 108010059993 Vancomycin Proteins 0.000 abstract 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 abstract 1
- 229960005484 daptomycin Drugs 0.000 abstract 1
- 229960003907 linezolid Drugs 0.000 abstract 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 abstract 1
- 229960001019 oxacillin Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 abstract 1
- 229960003165 vancomycin Drugs 0.000 abstract 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261644944P | 2012-05-09 | 2012-05-09 | |
US201261737239P | 2012-12-14 | 2012-12-14 | |
PCT/US2013/040329 WO2013170015A1 (en) | 2012-05-09 | 2013-05-09 | Bacteriophage lysin and antibiotic combinations against gram positive bacteria |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN02437A true IN2014MN02437A (ja) | 2015-07-10 |
Family
ID=49551273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2437MUN2014 IN2014MN02437A (ja) | 2012-05-09 | 2013-05-09 |
Country Status (16)
Country | Link |
---|---|
US (5) | US10813983B2 (ja) |
EP (2) | EP2849782B1 (ja) |
JP (4) | JP6608697B2 (ja) |
KR (3) | KR20230113404A (ja) |
CN (1) | CN104736172A (ja) |
AU (3) | AU2013259512B2 (ja) |
BR (1) | BR112014027842A2 (ja) |
CA (1) | CA2872902A1 (ja) |
DK (1) | DK2849782T3 (ja) |
ES (1) | ES2784136T3 (ja) |
HK (2) | HK1208799A1 (ja) |
IL (3) | IL235527B2 (ja) |
IN (1) | IN2014MN02437A (ja) |
MX (2) | MX2014013586A (ja) |
RU (2) | RU2018121290A (ja) |
WO (1) | WO2013170015A1 (ja) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9499594B2 (en) | 2012-05-09 | 2016-11-22 | Contrafect Corporation | Biofilm prevention, disruption and treatment with bacteriophage lysin |
IL235527B2 (en) | 2012-05-09 | 2023-10-01 | Contrafect Corp | Combinations of bacteriophage lysine and antibiotics against gram-positive bacteria |
WO2015200783A2 (en) * | 2014-06-26 | 2015-12-30 | The Rockefeller University | Acinetobacter lysins |
AU2016231141B2 (en) * | 2015-03-12 | 2022-03-03 | Micreos Human Health B.V. | Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection |
US11357833B2 (en) * | 2015-09-17 | 2022-06-14 | Contrafect Corporation | Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby |
DK3454888T3 (da) * | 2016-05-12 | 2021-04-26 | Contrafect Corp | Bouillon-mikrofortyndingsfremgangsmåde til evaluering og bestemmelse af minimal inhibitorisk koncentration for antibakterielle polypeptider |
DK3641753T3 (da) | 2017-06-19 | 2022-12-12 | Univ Syddansk | Bacitracin og/eller daptomycin kombineret med cannabidiol til behandling af bakterieinfektioner |
CN116603056A (zh) * | 2017-07-10 | 2023-08-18 | 康特拉费克特公司 | 裂解蛋白抗菌活性的血液组分强化及其方法和用途 |
RU2020128276A (ru) * | 2018-02-26 | 2022-03-29 | Контрафект Корпорейшн | МОДИФИЦИРОВАННЫЕ ЛИЗИНЫ PlySs2 И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ |
US20210260070A1 (en) * | 2018-06-22 | 2021-08-26 | Contrafect Corporation | Lysin cf-301 resensitizes methicillin-resistant staphylococcus aureua (mrsa) to penicillin derivatives and first generation cephalosporins |
CN109668873B (zh) * | 2018-12-05 | 2021-03-16 | 山东恒业生物技术有限公司 | 一种活载体疫苗活性检测装置及其使用方法 |
US20220127628A1 (en) * | 2019-02-05 | 2022-04-28 | Elanco Us Inc. | A genetically modified lactobacillus and uses thereof |
BR112021018219A2 (pt) * | 2019-03-22 | 2022-01-18 | Contrafect Corp | Método de tratamento de endocardite infecciosa |
CA3136461A1 (en) * | 2019-04-11 | 2020-10-15 | Contrafect Corporation | Method of treating and preventing bone and joint infections |
CN114845708A (zh) * | 2019-12-19 | 2022-08-02 | 乔治亚州大学研究基金会 | 用于治疗细菌感染和增强抗生素的化合物 |
CA3178761A1 (en) * | 2020-05-19 | 2021-11-25 | Raymond Schuch | Modified plyss2 lysins and antibiotic combinations for use against gram-positive bacteria |
RU2755817C1 (ru) * | 2020-07-22 | 2021-09-21 | Федеральное Государственное бюджетное научное учреждение "Федеральный научный центр биологических систем и агротехнологий российской академии наук" | Способ снижения грамположительной микрофлоры в кишечнике птицы |
KR102528412B1 (ko) * | 2020-09-08 | 2023-05-04 | 클립스비엔씨 주식회사 | 신규한 포도상구균 감염 질환의 예방 또는 치료용 조성물 |
WO2022261360A1 (en) * | 2021-06-09 | 2022-12-15 | Contrafect Corporation | Plyss2 lysins and variants thereof for use against multidrug resistant gram-positive bacteria |
CN115105491B (zh) * | 2022-07-08 | 2023-12-22 | 东北农业大学 | 丝氨酸在制备抑制猪链球菌药物中的用途 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8108587A (en) | 1986-10-08 | 1988-05-06 | David Bernstein | Method for exposing group a streptococcal antigens and an improved diagnostic test for the identification of group a streptococci |
CA1315229C (en) | 1987-06-10 | 1993-03-30 | Patrick J. Baker | Chromatographic purification process |
US6121036A (en) * | 1996-04-15 | 2000-09-19 | Ghanbari; Hossein A. | Compositions containing bacteriophages and methods of using bacteriophages to treat infections |
US6264945B1 (en) | 1997-10-31 | 2001-07-24 | Vincent A Fischetti | Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections |
US6248324B1 (en) | 1997-10-31 | 2001-06-19 | Vincent Fischetti | Bacterial phage associated lysing enzymes for treating dermatological infections |
US5997862A (en) | 1997-10-31 | 1999-12-07 | New Horizons Diagnostics Corporation | Therapeutic treatment of group A streptococcal infections |
US6254866B1 (en) | 1997-10-31 | 2001-07-03 | New Horizons Diagnostics Corporation | Use of phage associated lytic enzymes for treating bacterial infections of the digestive tract |
US20060292135A1 (en) | 1997-10-31 | 2006-12-28 | Lawrence Loomis | Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl |
KR20020000217A (ko) | 1999-02-25 | 2002-01-05 | 뉴 호라이즌스 다이아그노스틱스, 인코포레이티드 | 스트렙토코커스 감염의 예방 및 치료 방법 |
US6056955A (en) | 1999-09-14 | 2000-05-02 | Fischetti; Vincent | Topical treatment of streptococcal infections |
US6444813B2 (en) | 2000-02-02 | 2002-09-03 | Pharmacia & Upjohn Company | Linezolid-crystal form II |
AU2003291614A1 (en) | 2002-05-17 | 2004-04-08 | New Horizons Diagnostics Corporation | Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis |
US7569223B2 (en) | 2004-03-22 | 2009-08-04 | The Rockefeller University | Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions |
EP1744779A2 (en) | 2004-03-24 | 2007-01-24 | The Rockfeller University | Lytic enzymes and spore surface antigen for detection and treatment of "bacillus anthracis" bacteria and spores |
WO2008018854A2 (en) | 2005-06-06 | 2008-02-14 | The Rockefeller University | Bactiophage lysins for bacillus anthracis |
US7582291B2 (en) | 2005-06-30 | 2009-09-01 | The Rockefeller University | Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria |
ATE491026T1 (de) | 2005-08-24 | 2010-12-15 | Univ Rockefeller | Ply-gbs-lysinmutanten |
WO2009029192A1 (en) | 2007-08-24 | 2009-03-05 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Surfactant-based antimicrobial solution for inhalation |
WO2010002959A2 (en) | 2008-07-03 | 2010-01-07 | The Rockefeller University | A chimeric bacteriophage lysin with activity against staphylococci bacteria |
KR101016918B1 (ko) | 2009-01-08 | 2011-02-25 | 주식회사 인트론바이오테크놀로지 | 박테리아 특이적 넓은 항균 활성을 갖는 신규한 리신 단백질 |
WO2011091412A1 (en) | 2010-01-25 | 2011-07-28 | Alere Scarborough, Inc. | A25 bacteriophage lysin |
WO2012145530A2 (en) * | 2011-04-20 | 2012-10-26 | Visa International Service Association | Managing electronic tokens in a transaction processing system |
WO2012145573A2 (en) | 2011-04-21 | 2012-10-26 | Universiteit Utrecht Holding Bv | Streptococcus bacteriophage lysins for treatment of gram positive bacteria in companion animals and livestock |
US9034322B2 (en) * | 2011-04-21 | 2015-05-19 | The Rockefeller University | Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria |
US9016640B2 (en) | 2011-04-22 | 2015-04-28 | Rks Design, Inc. | Instrument retention assembly |
EP2993181A1 (en) | 2011-04-27 | 2016-03-09 | Lysando AG | New antimicrobial agents |
US9499594B2 (en) * | 2012-05-09 | 2016-11-22 | Contrafect Corporation | Biofilm prevention, disruption and treatment with bacteriophage lysin |
IL235527B2 (en) | 2012-05-09 | 2023-10-01 | Contrafect Corp | Combinations of bacteriophage lysine and antibiotics against gram-positive bacteria |
-
2013
- 2013-05-09 IL IL235527A patent/IL235527B2/en unknown
- 2013-05-09 EP EP13787128.1A patent/EP2849782B1/en active Active
- 2013-05-09 RU RU2018121290A patent/RU2018121290A/ru unknown
- 2013-05-09 US US14/399,575 patent/US10813983B2/en active Active
- 2013-05-09 CN CN201380036510.8A patent/CN104736172A/zh active Pending
- 2013-05-09 ES ES13787128T patent/ES2784136T3/es active Active
- 2013-05-09 BR BR112014027842A patent/BR112014027842A2/pt not_active Application Discontinuation
- 2013-05-09 AU AU2013259512A patent/AU2013259512B2/en active Active
- 2013-05-09 EP EP20158873.8A patent/EP3685851A1/en active Pending
- 2013-05-09 RU RU2014149351A patent/RU2659208C2/ru active
- 2013-05-09 IL IL308477A patent/IL308477A/en unknown
- 2013-05-09 MX MX2014013586A patent/MX2014013586A/es unknown
- 2013-05-09 JP JP2015511698A patent/JP6608697B2/ja active Active
- 2013-05-09 KR KR1020237023634A patent/KR20230113404A/ko active Application Filing
- 2013-05-09 WO PCT/US2013/040329 patent/WO2013170015A1/en active Application Filing
- 2013-05-09 KR KR1020147034614A patent/KR102310387B1/ko active Application Filing
- 2013-05-09 KR KR1020217031525A patent/KR20210121313A/ko not_active Application Discontinuation
- 2013-05-09 DK DK13787128.1T patent/DK2849782T3/da active
- 2013-05-09 CA CA2872902A patent/CA2872902A1/en active Pending
- 2013-05-09 IN IN2437MUN2014 patent/IN2014MN02437A/en unknown
- 2013-06-04 US US13/909,618 patent/US9889181B2/en active Active
-
2014
- 2014-11-07 MX MX2021011843A patent/MX2021011843A/es unknown
-
2015
- 2015-09-24 HK HK15109410.6A patent/HK1208799A1/xx unknown
- 2015-12-16 HK HK15112347.8A patent/HK1211484A1/xx unknown
-
2017
- 2017-12-20 US US15/848,886 patent/US20180221456A1/en not_active Abandoned
-
2018
- 2018-04-24 AU AU2018202845A patent/AU2018202845B2/en active Active
- 2018-04-27 JP JP2018086685A patent/JP2018138045A/ja not_active Withdrawn
-
2019
- 2019-12-06 JP JP2019221319A patent/JP2020054370A/ja active Pending
-
2020
- 2020-05-21 IL IL274832A patent/IL274832A/en unknown
- 2020-09-16 AU AU2020233683A patent/AU2020233683A1/en not_active Abandoned
- 2020-09-25 US US17/033,195 patent/US20210008175A1/en not_active Abandoned
-
2021
- 2021-01-05 US US17/141,692 patent/US20210128696A1/en not_active Abandoned
-
2022
- 2022-01-20 JP JP2022007043A patent/JP2022058682A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014MN02437A (ja) | ||
MX2023003461A (es) | Tratamiento de infeccion por clostridium difficile. | |
MX2017014020A (es) | Terapia antimicrobiana. | |
PH12015502401A1 (en) | Compositions and methods for enhancing microbial stability | |
TR201820333T4 (tr) | Bakteri Suşları İçeren Bileşimler | |
PH12016501512B1 (en) | Treatment for resistant acne | |
MX2019009132A (es) | Composiciones bacterianas sinergicas y sus metodos de produccion y usos. | |
ZA201908447B (en) | Bacitracin and/or daptomycin combined with cannabidiol for treatment of bacterial infections | |
IN2014MN02438A (ja) | ||
MX346664B (es) | Una composicion que comprende un agente antibiotico y un agente dispersante o un agente antiadhesivo. | |
GB2530921A (en) | C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficency | |
GB2548277A (en) | Antibiofilm compositions | |
GB2543453A (en) | Acinetobacter lysins | |
HRP20170987T1 (hr) | Fibrinolitički pripravci koji sadrže bromelain i natokinazu za sprječavanje i liječenje flebotrombotičkih stanja | |
PH12014501239A1 (en) | Thymol and totarol antibacterial composition | |
AU2016323967A8 (en) | Compositions and methods for the treatment and prevention of radiation dermatitis | |
SG11201702011SA (en) | Agent for promoting growth of nonpathogenic oral indigenous bacteria or agent for improving oral bacterial flora, and composition for oral use | |
MX2018007838A (es) | Silice recubierta de mucina para acumulacion bacteriana. | |
WO2018083314A3 (en) | Use of phenothiazine derivative in the treatment of infectious purpura or purpura fulminans | |
IN2014CN03886A (ja) | ||
WO2015063608A3 (en) | Prevention and dispersion of biolfilm | |
MX2013012603A (es) | Vancomicina liposomal para el tratamiento de infecciones por estafilococo aureus resistente a la meticilina (sarm). | |
MY167425A (en) | An antimicrobial composition for inhibiting bacterial biofilm | |
MX2015009505A (es) | Actividad antimicrobiana "in vitro" de la combinacion de peptidos antibiocidas de alacran con antibioticos de uso comun. | |
UA90789U (uk) | Спосіб профілактики гнійних ускладнень та ранової інфекції після екстракції зуба бактеріальною суспензією на основі bacillus subtilis 090 |